161 related articles for article (PubMed ID: 26859127)
1. Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis.
Wang W; Wang F; Zong G; Liu R; Zhang Y; Luan Y; Xu L; Xuan J
Int J Clin Exp Med; 2015; 8(9):16043-9. PubMed ID: 26629110
[TBL] [Abstract][Full Text] [Related]
3. The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.
Vilorio-Marqués L; Martín V; Diez-Tascón C; González-Sevilla MF; Fernández-Villa T; Honrado E; Davila-Batista V; Molina AJ
Sci Rep; 2017 Oct; 7(1):13806. PubMed ID: 29061982
[TBL] [Abstract][Full Text] [Related]
4. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.
Wang X; Zhao H; Lv L; Bao L; Wang X; Han S
Sci Rep; 2016 Jan; 6():19239. PubMed ID: 26754405
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
Du XM; Wang LH; Chen XW; Li YX; Li YC; Cao YW
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):305-312. PubMed ID: 27376796
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
8. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
10. EZH2 overexpression is associated with poor prognosis in patients with glioma.
Zhang Y; Yu X; Chen L; Zhang Z; Feng S
Oncotarget; 2017 Jan; 8(1):565-573. PubMed ID: 27880940
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
He LJ; Cai MY; Xu GL; Li JJ; Weng ZJ; Xu DZ; Luo GY; Zhu SL; Xie D
Asian Pac J Cancer Prev; 2012; 13(7):3173-8. PubMed ID: 22994729
[TBL] [Abstract][Full Text] [Related]
12. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
He LR; Liu MZ; Li BK; Jia WH; Zhang Y; Liao YJ; Chen YC; Zhang LJ; Guan XY; Zeng YX; Kung HF; Xie D
Int J Cancer; 2010 Jul; 127(1):138-47. PubMed ID: 19904743
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.
Peng L; Zhan P; Zhou Y; Fang W; Zhao P; Zheng Y; Xu N
Mol Biol Rep; 2012 Oct; 39(10):9473-84. PubMed ID: 22729879
[TBL] [Abstract][Full Text] [Related]
14. Role of EZH2 protein expression in gastric carcinogenesis among Asians: a meta-analysis.
Guo L; Yang TF; Liang SC; Guo JX; Wang Q
Tumour Biol; 2014 Jul; 35(7):6649-56. PubMed ID: 24705718
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysis.
Chen S; Huang L; Sun K; Wu D; Li M; Li M; Zhong B; Chen M; Zhang S
PLoS One; 2015; 10(5):e0125480. PubMed ID: 25974088
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 as a prognostic biomarker in gastrointestinal cancer: a meta-analysis.
Jiang Q; Sun Y; Liu X
Biomarkers; 2019 Sep; 24(6):510-516. PubMed ID: 31244335
[No Abstract] [Full Text] [Related]
17. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.
Fujii S; Ochiai A
Cancer Sci; 2008 Apr; 99(4):738-46. PubMed ID: 18377425
[TBL] [Abstract][Full Text] [Related]
18. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
20. Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression.
Bremer SCB; Conradi LC; Mechie NC; Amanzada A; Mavropoulou E; Kitz J; Ghadimi M; Ellenrieder V; Ströbel P; Hessmann E; Gaedcke J; Bohnenberger H
Digestion; 2021; 102(2):227-235. PubMed ID: 31694013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
